Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,604

Document Document Title
WO/2018/071547A1
This document discloses a powder formulation of lamotrigine for oral administration. Also disclosed is a suspension of lamotrigine and a method of treating diseases.  
WO/2018/060076A1
The present invention relates to novel triazole derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmf...  
WO/2018/060071A1
The present invention relates to novel triazole derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmf...  
WO/2018/049092A1
Small molecule inhibitors (SMIs) of the Prolactin receptor, pharmaceutical compositions of the SMIs, and methods for treating patients suffering from disorders characterized increased expression or excitation of the Prolactin receptor, i...  
WO/2018/030466A1
The purpose of the present invention is to provide a heterocyclic compound that can have GCN2-inhibiting activity and is expected to be useful in the prevention and treatment of GCN 2-related diseases and the like, including cancer. Prov...  
WO/2018/015328A1
The present invention relates to compounds of formula (I) a compound of formula (1') as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions co...  
WO/2017/204318A1
Provided is a novel compound having an antagonism to P2X3 and/or P2X2/3 receptors. A compound represented by formula (I) [wherein: R1 represents an optionally substituted alkyl group, etc.; R2 represents an optionally substituted aromati...  
WO/2017/204316A1
The present invention provides a novel compound having P2X3 and/or P2X2/3 receptor antagonism. A compound represented by formula (I): (wherein, R1 represents a substituted or unsubstituted alkyl or the like, R2 represents a substituted o...  
WO/2017/160569A1
The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonist...  
WO/2017/156262A1
Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HBV and/or HDV and/or HIV infection with one or more nucleotide analogs  
WO/2017/144708A3
An antiviral compound for use in the treatment of negative-sense, single-stranded RNA [herein after ssRNA] virus infections different from the Influenza A and Influenza B virus infections wherein said antiviral compound is of general for...  
WO/2017/098440A1
The present invention relates to LpxC antibacterial compounds of Formula (1A), corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions:, compound preparation, treatment methods and uses for bact...  
WO/2017/089301A1
The present invention relates to a compound according to formula (I) wherein X represents a bond or -(CRaRb)n-, wherein Ra and Rb each independently represents hydrogen, (C1-C4)alkyl or Ra and Rb together with the carbon atom to which th...  
WO/2017/051354A1
Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the p...  
WO/2017/005567A1
The invention relates to N-(tetrazole-5-yl)- and N-(triazole-5-yl)aryl carboxamide derivatives of the general formula (I) as herbicides. In said formula (I), V, X, and Z represent groups such as hydrogen, and organic groups such as alkyl...  
WO/2017/003895A1
The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (I) and (II) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). ...  
WO/2016/171249A1
Provided is the compound represented by formula (I) (in the formula, Y1 is O or the like; Z1 is, C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently hydrogen atoms or the like; R1 is a s...  
WO/2016/162688A1
The present invention discloses a method to discover selective inhibitors of phosphatases. Thus the invention provides a method for screening a test compound to determine whether the compound binds a holophosphatase selectively or non-se...  
WO/2016/162689A1
The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated ...  
WO/2016/116058A1
The present invention relates to a triazine heterocyclic compound with nematicidal activity and a preparation method therefor and usage thereof. Specifically, disclosed are a compound of formula (I) or an optical isomer, a cis-trans isom...  
WO/2016/094729A1
Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of G...  
WO/2016/089208A2
The present invention is directed to compounds having formula (I): A-L-R1, wherein A is an anticancer agent comprising at least one group selected from the group comprising OH, NH and NH2 and L is a direct bond or L is a linker and R1 is...  
WO/2016/089208A3
The present invention is directed to compounds having formula (I): A-L-R1, wherein A is an anticancer agent comprising at least one group selected from the group comprising OH, NH and NH2 and L is a direct bond or L is a linker and R1 is...  
WO/2016/081736A1
The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula (1), which are agonists of GPR139, certain compounds encompassed by formula (1), pharmaceutical compo...  
WO/2016/037005A1
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. ...  
WO/2016/023877A1
The invention provides novel compounds having the general formula wherein R1, R2, R3, X and a are as described in the description and in the claims, as well as or pharmaceutically acceptable salts thereof. The invention also contains com...  
WO/2015/189117A1
The invention relates to novel, heterobicyclically substituted 4-oxobutane acid derivatives, to methods for the production thereof, to the use thereof alone or in combination for treating and/or preventing illnesses, and to the use there...  
WO/2015/179864A1
Disclosed herein are compositions and methods for stabilizing a luminogenic substrate such as coelenterazine or a functional analog thereof. The functional analog may be furimazine. The composition may include the luminogenic substrate, ...  
WO/2015/169718A1
The invention relates to novel compounds of formula (I), in which R1, R2, n, V1, V2, Q, W, X, and Y have the meanings specified in the description, to a plurality of methods, and to intermediate products for producing said compounds, and...  
WO/2015/163427A1
The present invention provides: a novel disubstituted 1, 2, 4-triazine compound that has an aldosterone synthase inhibitory activity and is useful in the prevention and/or treatment of various diseases or symptoms involving aldosterone, ...  
WO/2015/150362A3
The present invention relates to novel, chiral 2,5- disubstituted cyclopentanecarboxylic acid derivatives, to a method for the production thereof, to the use thereof alone or in combinations for the treatment and/or prophylaxis of diseas...  
WO/2015/150362A2
The present invention relates to novel, chiral 2,5- disubstituted cyclopentanecarboxylic acid derivatives, to a method for the production thereof, to the use thereof alone or in combinations for the treatment and/or prophylaxis of diseas...  
WO/2015/150366A1
The invention relates to novel, cyclically substituted phenol ether derivatives, to methods for the production thereof, to the use thereof alone or in combination for treating and/or preventing illnesses, and to the use thereof for produ...  
WO/2015/150363A1
The invention relates to novel 2,5-disubstituted cyclopentane carboxylic acid derivatives, to methods for the preparation thereof, to the use thereof alone or in combination for the treatment and/or prevention of disorders, and to the us...  
WO/2015/150364A1
The present application relates to novel substituted 4-(1,2,3-benzotriazine-4-on-3-yl)butane acid derivatives, to methods for the preparation thereof, to the use thereof alone or in combination for the treatment and/or prevention of diso...  
WO/2015/143535A1
Small molecule inhibitors GP120-mediated HIV infections, methods for identifying the same, and methods and uses employing of these compounds in treatment, inhibition or prevention of HIV infection are provided. The compounds have a struc...  
WO/2015/140196A1
The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to ...  
WO/2015/138919A1
Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. In one embodiment, the compounds described herein mimic...  
WO/2015/121336A1
The present invention relates to polymers comprising as monomer units one or more compounds having at least a triazine or a pyrimidine core. Preferably, the polymer of the present invention comprises as monomer unit the compound of formu...  
WO2015120800A1
Provided is a nitrogen heterocyclic compound or pharmaceutically acceptable salts, hydrates and prodrugs of the nitrogen heterocyclic compound, wherein the nitrogen heterocyclic compound has a remarkable anti-tumor effect. Also provided ...  
WO/2015/093534A1
[Problem] To provide a novel triazinone compound having inhibitory activity on T-type potential-dependent calcium channels, and which is useful for treating pain, chronic kidney disease, and atrial fibrillation in particular. [Solution] ...  
WO/2015/092819A2
The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the ...  
WO/2015/092819A3
The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the ...  
WO/2015/067193A1
The present invention belongs to the technical field of medicine, and relates to a triazine compound for combating coccidiosis in chickens, a method of preparing said compound, and a use of said compound, the structure of the compound be...  
WO/2015/067650A1
The invention relates to novel substituted 1,2,4-triazine-3,5-dione deratives, to a method for the production thereof, to the use thereof either alone or in combination for the treatment and/or prophylaxis of diseases, and to the use the...  
WO/2015/061189A1
The disclosure provides modular triazine-based unimolecular initiator compounds useful in controlled radical polymerizations of vinyl-containing monomers.  
WO/2015/004028A1
The present application relates to new heterocyclic compounds of formula (I), wherein D stands for a substructure of formula (I-A), a method for the production thereof and the use thereof for combatting animal pests, including arthropods...  
WO/2014/154829A1
The present invention provides a compound of Formula (I) or Formula (II): or an agronomically acceptable salt thereof, wherein :- R2 is selected from the group consisting of A1, A2, A3, A4 and A5 wherein X1 is N or CR7; X2 is N or CR8; X...  
WO/2014/157687A1
Provided are novel compounds having Syk-inhibiting effects and cell growth-inhibiting effects. Also provided is a medicine that is useful for prevention and/or treatment of cancer, allergic diseases or autoimmune diseases based on Syk-in...  
WO/2014/114185A1
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in thera...  

Matches 1 - 50 out of 1,604